| pubmed-article:16054370 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0030940 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0870071 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C1947946 | lld:lifeskim |
| pubmed-article:16054370 | lifeskim:mentions | umls-concept:C0289132 | lld:lifeskim |
| pubmed-article:16054370 | pubmed:issue | 18 | lld:pubmed |
| pubmed-article:16054370 | pubmed:dateCreated | 2005-8-15 | lld:pubmed |
| pubmed-article:16054370 | pubmed:abstractText | The increasing resistance of the malarial parasite to antimalarial drugs is a major contributor to the reemergence of the disease and increases the need for new drug targets. The two aspartic proteases, plasmepsins I and II, from Plasmodium falciparum have recently emerged as potential targets. In an effort to inhibit these hemoglobinases, a series of inhibitors encompassing a basic hydroxyethylamine transition state isostere as a central fragment were prepared. The synthesized compounds were varied in the P1' position and exhibited biological activities in the range of 31 to >2000 nM. To try to rationalize the results, molecular docking and 3D-QSAR analysis were used. | lld:pubmed |
| pubmed-article:16054370 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16054370 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16054370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16054370 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16054370 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16054370 | pubmed:issn | 0968-0896 | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:SabnisYogesh... | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:HallbergAnder... | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:SamuelssonBer... | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:KarlénAndersA | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:NötebergDanie... | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:HamelinkEliza... | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:VrangLottaL | lld:pubmed |
| pubmed-article:16054370 | pubmed:author | pubmed-author:MuthasDanielD | lld:pubmed |
| pubmed-article:16054370 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16054370 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:16054370 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:16054370 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16054370 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16054370 | pubmed:pagination | 5371-90 | lld:pubmed |
| pubmed-article:16054370 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:meshHeading | pubmed-meshheading:16054370... | lld:pubmed |
| pubmed-article:16054370 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16054370 | pubmed:articleTitle | Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II. | lld:pubmed |
| pubmed-article:16054370 | pubmed:affiliation | Department of Medicinal Chemistry, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden. | lld:pubmed |
| pubmed-article:16054370 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16054370 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
